{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:04Z","timestamp":1790797084348,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T00:00:00Z","timestamp":1362355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2013,4]]},"abstract":"\n Objective<\/jats:title>\n \n Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (\n EM<\/jats:styled-content>\n ) and chronic migraine (\n CM<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Several classes of medications are used both on\u2010 and off\u2010label for the prevention of migraine, including\n \u03b2<\/jats:italic>\n \u2010blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti\u2010epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxin\n A<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Preventive medication use and reasons for discontinuation were collected in an international, Web\u2010based, cross\u2010sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache\u2010related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and\n EM<\/jats:styled-content>\n or\n CM<\/jats:styled-content>\n . Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n One thousand one hundred and sixty\u2010five respondents completed the survey. Only 28.3% of\n EM<\/jats:styled-content>\n and 44.8% of\n CM<\/jats:styled-content>\n respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4% of those with\n EM<\/jats:styled-content>\n and 65.9% with\n CM<\/jats:styled-content>\n . The mean number of prophylactic medications ever used was 2.92 for\n EM<\/jats:styled-content>\n and 3.94 for\n CM<\/jats:styled-content>\n . Antidepressants were used most frequently (\n EM<\/jats:styled-content>\n 60.9%;\n CM<\/jats:styled-content>\n 54.7%), followed by\n \u03b2<\/jats:italic>\n \u2010blockers (\n EM<\/jats:styled-content>\n 35.4%;\n CM<\/jats:styled-content>\n 36.8%) and anti\u2010epileptics (\n EM<\/jats:styled-content>\n 28.6%;\n CM<\/jats:styled-content>\n 36.3%). Odds of preventive medication use were higher among\n CM<\/jats:styled-content>\n than\n EM<\/jats:styled-content>\n , adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95% confidence interval 2.15 to 3.57). Greater headache\u2010related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Less than half the persons with\n EM<\/jats:styled-content>\n and\n CM<\/jats:styled-content>\n were currently using preventive medication for migraine, with treatment rates being higher for\n CM<\/jats:styled-content>\n , as expected. Those with\n CM<\/jats:styled-content>\n tried more medications than those with\n EM<\/jats:styled-content>\n , possibly reflecting higher levels of treatment need.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/head.12055","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T11:28:32Z","timestamp":1357298912000},"page":"644-655","source":"Crossref","is-referenced-by-count":341,"title":["Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (\n IBMS\u2010II<\/scp>\n )"],"prefix":"10.1111","volume":"53","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[{"name":"Neurology Center Encinitas CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Bloudek","sequence":"additional","affiliation":[{"name":"Allergan Inc. Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Becker","sequence":"additional","affiliation":[{"name":"University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine and the Montefiore Headache Center Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh F.","family":"Varon","sequence":"additional","affiliation":[{"name":"Allergan Inc. Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Maglinte","sequence":"additional","affiliation":[{"name":"Allergan Inc. Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa K.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"United BioSource Corporation Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane K.","family":"Kawata","sequence":"additional","affiliation":[{"name":"United BioSource Corporation Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine and the Montefiore Headache Center Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01369.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/23.5.1020"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01288.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01172.x"},{"issue":"1","key":"e_1_2_8_8_1","first-page":"9","article-title":"The International Classification of Headache Disorders: 2nd edition","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492"},{"key":"e_1_2_8_12_1","unstructured":"RamadanNM SilbersteinSD FreitagFG GilbertTT FrishbergBM.Evidence\u2010Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine.2000. US Headache Consortium. Available at:http:\/\/www.aan.com\/professionals\/practice\/pdfs\/gl0090.pdf(accessed 01\/17\/2011)."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00631.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.12055","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.12055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:44:34Z","timestamp":1762083874000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.12055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/head.12055"],"URL":"https:\/\/doi.org\/10.1111\/head.12055","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,4]]}}}